Shanghai Medicine: Levofloxacin Mesylate Sustained-release Tablets Approved for Production

Shanghai Pharmaceuticals announced that recently, its subsidiary Shanghai Sundise Pharmaceutics Co., Ltd. received the "Drug Registration Certificate" issued by the National Medical Products Administration for its sustained-release tablets of Citric Acid Tofacitinib. The drug has been approved for production. Citric Acid Tofacitinib sustained-release tablets are used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Originally developed by Pfizer, the drug was first launched in the United States in 2016. In January 2024, Sundise Pharmaceutics submitted an application for registration and listing of the drug to the National Medical Products Administration, which was accepted. As of the date of this announcement, the company has invested approximately RMB 19.4192 million in research and development expenses for this drug.